Raymond James Trust N.A. Grows Stake in Amgen, Inc. (AMGN)
Raymond James Trust N.A. increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,025 shares of the medical research company’s stock after purchasing an additional 475 shares during the period. Raymond James Trust N.A.’s holdings in Amgen were worth $11,199,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Kwmg LLC purchased a new stake in Amgen during the second quarter valued at approximately $108,000. Mainstay Capital Management LLC ADV purchased a new stake in Amgen during the second quarter valued at approximately $111,000. Braun Bostich & Associates Inc. purchased a new stake in Amgen during the first quarter valued at approximately $113,000. WealthTrust Fairport LLC purchased a new stake in Amgen during the first quarter valued at approximately $121,000. Finally, Gables Capital Management Inc. purchased a new stake in Amgen during the first quarter valued at approximately $174,000. 82.48% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:AMGN opened at $202.77 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 3.39 and a quick ratio of 3.12. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $210.19. The firm has a market cap of $134.17 billion, a P/E ratio of 16.12, a P/E/G ratio of 2.02 and a beta of 1.40.
A number of brokerages have recently issued reports on AMGN. JPMorgan Chase & Co. increased their price objective on shares of Amgen from $191.00 to $192.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 11th. Jefferies Financial Group reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research note on Monday, July 16th. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $207.00 price objective for the company in a research note on Tuesday, June 26th. Finally, Morgan Stanley increased their price objective on shares of Amgen from $210.00 to $212.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $204.90.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Story: Investing in Growth Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.